EU assessing Pfizer-Wyeth deal; Par Pharma ships Risperdal copy;

> European Union's competition services will examine U.S. drug manufacturer Pfizer's takeover of rival Wyeth, the largest pharmaceutical takeover deal in nearly a decade. Report

> Par Pharmaceutical started shipping its versions of the Johnson & Johnson antipsychotic drug Risperdal M-TAB. Par release

> Pfizer introduced its Toviaz overactive bladder drug along with a 12-week program of lifestyle changes to supplement drug treatment. Pfizer release

> Astellas Pharma U.S., the American subsidiary of the Japanese company, hired Dan Dunham as vice president of compliance. Report

> Two studies from AstraZeneca show that symptomatic gastroesophageal reflux disease (GERD) patients treated with Nexium experienced greater relief from nighttime heartburn and GERD-related sleep disturbances. AstraZeneca release

> Cardinal Health boosted its quarterly dividend by 25 percent in anticipation of a planned spinoff of its CareFusion clinical and medical products unit. Report

> Shares in the Danish biotech firm Genmab soared on Tuesday after U.S. advisers backed approval of its leukaemia drug Arzerra. Report

> A blood-pressure medicine has been shown to reverse the effects of early-stage liver failure in some patients. Report

> Canada's MDS has sold off its Phase II-IV clinical development ops to INC Research for $50 million. And with the focus at MDS shifting to early-stage research, executives say they have also put their central labs operation on the market. Report

> A small, early-stage clinical trial of an experimental skin cancer drug delivered some impressive results. Researchers for Plexxikon and Roche say that more than half of the patients taking PLX4032 (R7204) saw the extent of their malignant melanoma--the most lethal form of skin cancer--reduced by at least 30 percent. Report

> Questioning both the integrity of its late-stage data as well as its ability to demonstrate efficacy, the FDA has rejected ARCA Biopharma's heart failure drug Gencaro. Report

> With no white knight appearing from stage left with a buyout offer, the board at TorreyPines Therapeutics has decided to call it quits and join the ranks of the liquidated. Report

> A pair of PARP inhibitors--heralded as a promising new approach to fighting breast cancer--took center stage amid the torrent of new cancer data to flow through ASCO over the weekend. Report

> AstraZeneca and Merck are teaming up for an unusual, early-stage clinical program that combines two experimental cancer therapies. Report

And Finally... Microsoft bought Rosetta Biosoftware, a Merck unit, as part of an effort to expand into life-sciences software. Report